Novel Oral Treatment Reduced Liver Fat in MASH

The positive results of HU6 and DR10624 in reducing liver fat and improving liver health in MASH patients offer a potential breakthrough in treating a condition that currently lacks effective therapies. These promising outcomes from Phase 2 trials could pave the way for new treatment options in the liver disease space, attracting interest from biotech and pharma companies looking to address unmet medical needs.